Hjem › Myelodysplastiske syndromer › Kentucky
Myelodysplastiske syndromer kliniske forsøg i Kentucky
5 studier for Myelodysplastiske syndromer søger deltagere på steder i Kentucky.
Byer i Kentucky
Officiel studietekst (engelsk)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT07422480The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT06499285Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.